High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3

Episode 3 March 16, 2022 00:19:56
High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3
COR2ED Medical Education
High-Risk Cytogenetics in MM: Choosing the Best Treatment Regimen Ep 3

Mar 16 2022 | 00:19:56

/

Show Notes

COR2ED Medical Education: In this podcast episode, myeloma experts Dr. María Victoria Mateos (Haematologist at the University Hospital Salamanca, Spain) and Dr. Alexander Lesokhin (Associate Attending on the Myeloma Service at the Memorial Sloan Kettering Cancer Center, New York, NY, USA) discuss how they choose the best treatment regimen for patients with multiple myeloma and a high-risk cytogenetic profile. 

Firstly, they discuss the treatment options available for patients with high-risk cytogenetics in the US and in Europe. However, the key question is how to decide, for each individual, which treatment option is the best one. Dr. Mateos and Dr. Lesokhin discuss the factors they consider in these decisions in their clinical practice. Although the prior treatment is the most important consideration in the relapsed setting, the type of cytogenetic abnormality also plays a role. The experts specifically discuss treatment decisions in patients with extramedullary multiple myeloma: a difficult-to-treat population.

The speakers also discuss the future of myeloma treatment. How should trial design be adapted to better meet the needs of patients with a high-risk cytogenetic profile? What will be the role of CAR-T and bispecific antibodies in this population?

The experts conclude by summarising their key take-aways from the discussion.

Other Episodes

Episode 1

October 06, 2022 00:30:22
Episode Cover

HCC updates from ILCA and ESMO congressess 2022

COR2ED Medical Education: In this HCC CONNECT podcast HCC Experts Prof. Matthias Pinter and Prof. Jeroen Dekervel, discuss and debate the clinical implications of...

Listen

Episode 2

February 15, 2023 00:19:43
Episode Cover

PARPi and NHA combination therapy for patients with mCRPC – a US and EU perspective

COR2ED Medical Education: Dr Neal Shore, Uro-Oncologist and Chief Medical Officer for Genesis Care and Urology and Surgical Oncology in the United States and...

Listen

Episode 1

November 30, 2021 00:20:49
Episode Cover

The role of VEGFR-TKIs in the treatment of advanced RCC alone or in combination

Prof. Thomas Powles, a Medical Oncologist from Barts Cancer Centre in the UK and Prof. Georg Hutterer, a Urologist from the Medical University of...

Listen